3/11/2014

The FDA has granted Pluristem Therapeutics approval to use its new manufacturing plant in Haifa, Israel, allowing it to take part in advanced clinical studies in the U.S. The facility features the company's fully automated 3D cell expansion platform for manufacturing stem cells.

Full Story:
Globes (Israel)

Related Summaries